Literature DB >> 12783594

Leflunomide for the treatment of rheumatoid arthritis.

Corinne Miceli-Richard1, Maxime Dougados.   

Abstract

Leflunomide (Arava), Aventis Pharmaceuticals) is an immunomodulating drug that interferes with the metabolism of pyrimidine by inhibiting dihydro-orotate dehydrogenase (DHO-DH) in mitochondria, thereby blocking T- and B cell proliferation. Antibody production is also affected by DHO-DH blockade. Other immunomodulatory effects of leflunomide have also been reported. Symptomatic and structural effects of leflunomide in active rheumatoid arthritis have been strictly evaluated by double-blind, randomised, placebo-controlled studies that were aimed at validating its use in rheumatoid arthritis. Further trials are now required to confirm efficacy and safety of this drug in combination with other agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783594     DOI: 10.1517/14656566.4.6.987

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

2.  Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide.

Authors:  Violetta Dziedziejko; Mateusz Kurzawski; Krzysztof Safranow; Andrzej Ossowski; Jaroslaw Piatek; Miroslaw Parafiniuk; Dariusz Chlubek; Andrzej Pawlik
Journal:  Eur J Clin Pharmacol       Date:  2011-10-14       Impact factor: 2.953

3.  The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor.

Authors:  Edmond F O'Donnell; Katerine S Saili; Daniel C Koch; Prasad R Kopparapu; David Farrer; William H Bisson; Lijoy K Mathew; Sumitra Sengupta; Nancy I Kerkvliet; Robert L Tanguay; Siva Kumar Kolluri
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

4.  Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.

Authors:  Małgorzata Łączna; Damian Malinowski; Agnieszka Paradowska-Gorycka; Krzysztof Safranow; Violetta Dziedziejko; Andrzej Pawlik
Journal:  Eur J Clin Pharmacol       Date:  2021-06-23       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.